{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:45:32Z","timestamp":1792759532097,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.drugalcdep.2020.108137","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T11:19:52Z","timestamp":1593256792000},"page":"108137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["The state of the science in opioid policy research"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6009-8367","authenticated-orcid":false,"given":"Megan S.","family":"Schuler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-9000","authenticated-orcid":false,"given":"Sara E.","family":"Heins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1568-2097","authenticated-orcid":false,"given":"Rosanna","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Ann","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9690-7875","authenticated-orcid":false,"given":"Bryce","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Smucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie Liccardo","family":"Pacula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-458X","authenticated-orcid":false,"given":"Bradley D.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2020.108137_bib0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1198\/jasa.2009.ap08746","article-title":"Synthetic control methods for comparative case studies: estimating the effect of California\u2019s tobacco control program","volume":"105","author":"Abadie","year":"2010","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1176\/appi.ps.201700196","article-title":"State-targeted funding and technical assistance to increase access to medication treatment for opioid use disorder","volume":"69","author":"Abraham","year":"2018","journal-title":"Psychiatry Serv."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addbeh.2017.01.011","article-title":"Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: evidence from the National Survey of Drug Use and Health","volume":"69","author":"Ali","year":"2017","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1257\/pol.20170082","article-title":"Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids","volume":"10","author":"Alpert","year":"2018","journal-title":"Am. Econ. J. Econ. Policy"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.whi.2016.09.002","article-title":"A moral or medical problem? The relationship between legal penalties and treatment practices for opioid use disorders in pregnant women","volume":"26","author":"Angelotta","year":"2016","journal-title":"Womens Health Issues"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0030","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1073110518782948","article-title":"The impact of prescription drug monitoring programs on U.S. opioid prescriptions","volume":"46","author":"Ayres","year":"2018","journal-title":"J. Law Med. Ethics"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0040","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/MLR.0000000000000803","article-title":"Medicaid coverage of methadone maintenance and the use of opioid agonist therapy among pregnant women in specialty treatment","volume":"55","author":"Bachhuber","year":"2017","journal-title":"Med. Care"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.drugalcdep.2006.01.011","article-title":"The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone","volume":"84","author":"Bailey","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5055\/jom.2016.0322","article-title":"State-level and system-level opioid prescribing policies: the impact on provider practices and overdose deaths, a systematic review","volume":"12","author":"Beaudoin","year":"2016","journal-title":"J. Opioid Manag."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.7326\/M18-1243","article-title":"Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention\u2019s 2016 opioid guideline","volume":"169","author":"Bohnert","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0060","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.japh.2016.11.003","article-title":"Trends in naloxone prescriptions prescribed after implementation of a national academic detailing service in the Veterans Health Administration: a preliminary analysis","volume":"57","author":"Bounthavong","year":"2017","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2016.04.033","article-title":"Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: a comparative interrupted time series analysis","volume":"165","author":"Chang","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0070","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/pds.4404","article-title":"Impact of Florida\u2019s prescription drug monitoring program and pill mill law on high-risk patients: a comparative interrupted time series analysis","volume":"27","author":"Chang","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0075","first-page":"902","article-title":"Evaluation of patient migration patterns and related health care costs within a national Medicare advantage prescription drug plan after implementation of an oxycodone HCl extended-release access restriction","volume":"23","author":"Chen","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","article-title":"Fentanyl in the US heroin supply: a rapidly changing risk environment","volume":"46","author":"Ciccarone","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0090","first-page":"e164","article-title":"Medicaid prior authorization and opioid medication abuse and overdose","volume":"23","author":"Cochran","year":"2017","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0095","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0100","first-page":"429","article-title":"Mandatory minimum sentencing, drug purity and overdose rates","volume":"41","author":"Davies","year":"2010","journal-title":"Econ. Soc. Rev."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.forsciint.2017.10.008","article-title":"Fatal poisonings involving propoxyphene before and after voluntary withdrawal from the United States\u2019 market: an analysis from the state of Florida","volume":"280","author":"Delcher","year":"2017","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0110","series-title":"Prescription Drug Monitoring Programs, Opioid Abuse, and Crime","author":"Dhaval","year":"2018"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0115","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1377\/hlthaff.2014.1205","article-title":"Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002\u201311","volume":"34","author":"Dick","year":"2015","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0120","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1377\/hlthaff.2016.0448","article-title":"Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates","volume":"35","author":"Dowell","year":"2016","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0125","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.jclinepi.2013.03.020","article-title":"Approaches to inverse-probability-of-treatment\u2013weighted estimation with concurrent treatments","volume":"66","author":"Ellis","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.14078","article-title":"Association of punitive and reporting state policies related to substance use in pregnancy with rates of neonatal abstinence syndrome","volume":"2","author":"Faherty","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.drugalcdep.2017.07.015","article-title":"Trends in insurance coverage and treatment among persons with opioid use disorders following the Affordable Care Act","volume":"179","author":"Feder","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0140","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/M17-3074","article-title":"Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review","volume":"168","author":"Fink","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0145","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12913-017-2354-5","article-title":"Evaluating the impact of prescription drug monitoring program implementation: a scoping review","volume":"17","author":"Finley","year":"2017","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.05.014","article-title":"Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid","volume":"190","author":"Gertner","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0155","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2020.0050","article-title":"We need a taxonomy of state-level opioid policies","author":"Grant","year":"2020","journal-title":"JAMA Health Forum Insights"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107563","article-title":"Evidence for state, community and systems-level prevention strategies to address the opioid crisis","volume":"204","author":"Haegerich","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0165","series-title":"Drug Overdose Deaths in the United States, 1999\u20132018","author":"Hedegaard","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0170","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.2105\/AJPH.2019.305253","article-title":"Prescription opioids: a continuing contributor to the epidemic","volume":"109","author":"Heins","year":"2019","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0175","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/EDE.0000000000000547","article-title":"Diagnostics for confounding of time-varying and other joint exposures","volume":"27","author":"Jackson","year":"2016","journal-title":"Epidemiology"},{"issue":"Suppl. 2","key":"10.1016\/j.drugalcdep.2020.108137_bib0180","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1111\/j.1526-4637.2011.01126.x","article-title":"State-level strategies for reducing prescription drug overdose deaths: Utah\u2019s prescription safety program","volume":"12","author":"Johnson","year":"2011","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0185","series-title":"The Opioid Epidemic and Medicaid\u2019s Role in Facilitating Access to Treatment","author":"Kaiser Family Foundation","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0190","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/add.14248","article-title":"Effects of a prior authorization policy for extended-release\/long-acting opioids on utilization and outcomes in a state Medicaid program","volume":"113","author":"Keast","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0195","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2105\/AJPH.2015.302953","article-title":"Opioid overdose deaths and Florida\u2019s crackdown on pill mills","volume":"106","author":"Kennedy-Hendricks","year":"2016","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0200","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/hec.3258","article-title":"Examination of the synthetic control method for evaluating health policies with multiple treated units","volume":"25","author":"Kreif","year":"2016","journal-title":"Health Econ."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0205","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/jgs.15332","article-title":"Opioid prescriptions in older Medicare beneficiaries after the 2014 federal rescheduling of hydrocodone products","volume":"66","author":"Kuo","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0210","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.drugalcdep.2018.04.004","article-title":"Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States","volume":"188","author":"Lambdin","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0215","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamainternmed.2015.0914","article-title":"Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene","volume":"175","author":"Larochelle","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0220","first-page":"S243","article-title":"The economic burden of the opioid epidemic on states: the case of Medicaid","volume":"25","author":"Leslie","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0225","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/j.pain.0000000000000837","article-title":"Impact of the opioid safety initiative on opioid-related prescribing in veterans","volume":"158","author":"Lin","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0230","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1365-2753.2010.01504.x","article-title":"Applying a propensity score-based weighting model to interrupted time series data: improving causal inference in programme evaluation","volume":"17","author":"Linden","year":"2011","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0235","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12874-017-0434-1","article-title":"Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination","volume":"17","author":"Lusivika-Nzinga","year":"2017","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jsat.2018.01.001","article-title":"Gender differences in trends for heroin use and nonmedical prescription opioid use, 2007\u20132014","volume":"87","author":"Marsh","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/1468-0009.12436","article-title":"The association of state opioid misuse prevention policies with patient- and provider-related outcomes: a scoping review","volume":"98","author":"Mauri","year":"2020","journal-title":"Milbank Q."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0250","doi-asserted-by":"crossref","first-page":"504","DOI":"10.7326\/M19-2403","article-title":"Growth and distribution of buprenorphine-waivered providers in the United States, 2007\u20132017","volume":"172","author":"McBain","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addbeh.2018.03.014","article-title":"Opioid-overdose laws association with opioid use and overdose mortality","volume":"86","author":"McClellan","year":"2018","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0260","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jhealeco.2018.06.004","article-title":"The role of health insurance on treatment for opioid use disorders: evidence from the Affordable Care Act Medicaid expansion","volume":"60","author":"Meinhofer","year":"2018","journal-title":"J. Health Econ."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0265","series-title":"What America\u2019s Users Spend on Illegal Drugs, 2006\u20132016","author":"Midgette","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0270","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pds.4639","article-title":"Using trajectory models to assess the effect of hydrocodone upscheduling among chronic hydrocodone users","volume":"28","author":"Murimi","year":"2019","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0275","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drugpo.2018.05.013","article-title":"Assessing the effectiveness of New York\u2019s 911 Good Samaritan law-evidence from a natural experiment","volume":"58","author":"Nguyen","year":"2018","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0280","series-title":"The Future of Fentanyl and Other Synthetic Opioids","author":"Pardo","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0285","unstructured":"PDAPS, 2019. http:\/\/pdaps.org\/datasets\/pdmp-implementation-dates. (Accessed on Jan 10, 2020)."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0290","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugalcdep.2017.12.002","article-title":"Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings","volume":"184","author":"Pauly","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0295","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020477","article-title":"Statewide cross-sectional survey of emergency departments\u2019 adoption and implementation of the Ohio opioid prescribing guidelines and opioid prescribing practices","volume":"8","author":"Penm","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0300","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/pds.4376","article-title":"Decline in opioid prescribing after federal rescheduling of hydrocodone products","volume":"27","author":"Raji","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0305","series-title":"With a Little Help from My Friends: the Effects of Naloxone Access and Good Samaritan Laws on Opioid-Related Deaths","author":"Rees","year":"2017"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0310","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1377\/hlthaff.2016.0355","article-title":"Controlled substance lock-in programs: examining an unintended consequence of a prescription drug abuse policy","volume":"35","author":"Roberts","year":"2016","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0315","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0320","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2146\/ajhp130798","article-title":"Intranasal naloxone administration for treatment of opioid overdose","volume":"71","author":"Robinson","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0325","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1001\/jamainternmed.2015.3931","article-title":"Effect of Florida\u2019s prescription drug monitoring program and pill mill laws on opioid prescribing and use","volume":"175","author":"Rutkow","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0330","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1176\/appi.ps.201500228","article-title":"Medicaid coverage for methadone maintenance and use of opioid agonist therapy in specialty addiction treatment","volume":"67","author":"Saloner","year":"2016","journal-title":"Psychiatry Serv."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0335","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health","author":"SAMHSA","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0340","series-title":"The Opioid Crisis and the black\/African American Population: an Urgent Issue","author":"SAMHSA","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0345","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/sim.8080","article-title":"Optimal probability weights for estimating causal effects of time-varying treatments with marginal structural cox models","volume":"38","author":"Santacatterina","year":"2019","journal-title":"Stat. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0350","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s11606-019-05559-6","article-title":"Heterogeneity in prescription opioid pain reliever misuse across age groups: 2015-2017 National Survey on Drug Use and Health","volume":"35","author":"Schuler","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0355","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2105\/AJPH.2018.304338","article-title":"Impact of Medicaid expansion on access to opioid analgesic medications and medication-assisted treatment","volume":"108","author":"Sharp","year":"2018","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0360","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drugalcdep.2017.01.006","article-title":"Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever","volume":"173","author":"Shi","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drugalcdep.2018.09.016","article-title":"Recreational marijuana legalization and prescription opioids received by Medicaid enrollees","volume":"194","author":"Shi","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0370","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1002\/sim.5801","article-title":"Estimating parsimonious models of longitudinal causal effects using regressions on propensity scores","volume":"32","author":"Shinohara","year":"2013","journal-title":"Stat. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.21106\/ijma.284","article-title":"Opioid epidemic in the United States: empirical trends, and a literature review of social determinants and epidemiological, pain management, and treatment patterns","volume":"8","author":"Singh","year":"2019","journal-title":"Int. J. MCH AIDS"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0380","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jpain.2016.07.003","article-title":"Reducing opioid misuse: evaluation of a Medicaid controlled substance lock-in program","volume":"17","author":"Skinner","year":"2016","journal-title":"J. Pain"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0385","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jsat.2014.07.010","article-title":"Supply of buprenorphine waivered physicians: the influence of state policies","volume":"48","author":"Stein","year":"2015","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0390","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10742-014-0123-z","article-title":"Using propensity scores in difference-in-differences models to estimate the effects of a policy change","volume":"14","author":"Stuart","year":"2014","journal-title":"Health Serv. Outcomes Res. Methodol."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0395","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/10903127.2015.1076096","article-title":"Use of naloxone by emergency medical services during opioid drug overdose resuscitation efforts","volume":"20","author":"Sumner","year":"2016","journal-title":"Prehosp. Emerg. Care"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0400","doi-asserted-by":"crossref","first-page":"f174","DOI":"10.1136\/bmj.f174","article-title":"Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis","volume":"346","author":"Walley","year":"2013","journal-title":"BMJ"},{"issue":"799\u2013808","key":"10.1016\/j.drugalcdep.2020.108137_bib0405","first-page":"e791","article-title":"The effect of opioid prescribing guidelines on prescriptions by emergency physicians in Ohio","volume":"70","author":"Weiner","year":"2017","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0410","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamainternmed.2018.1007","article-title":"Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees","volume":"178","author":"Wen","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0415","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment","volume":"55","author":"Wen","year":"2017","journal-title":"Med. Care"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0420","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1377\/hlthaff.2016.1141","article-title":"States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees","volume":"36","author":"Wen","year":"2017","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0425","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-publhealth-040617-013507","article-title":"Designing difference in difference studies: best practices for public health policy research","volume":"39","author":"Wing","year":"2018","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0430","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.addbeh.2018.10.017","article-title":"Medical marijuana legalization and associated illicit drug use and prescription medication misuse among adolescents in the U.S","volume":"90","author":"Wong","year":"2019","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0435","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1017\/pan.2016.2","article-title":"Generalized synthetic control method: causal inference with interactive fixed effects models","volume":"25","author":"Xu","year":"2017","journal-title":"Polit. Anal."},{"key":"10.1016\/j.drugalcdep.2020.108137_bib0440","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.04.020","article-title":"State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies","volume":"189","author":"Xu","year":"2018","journal-title":"Drug Alcohol Depend."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620303021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620303021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:04:06Z","timestamp":1759827846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871620303021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":88,"alternative-id":["S0376871620303021"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108137","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The state of the science in opioid policy research","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108137"}}